TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31827357

Group type: EXPERIMENTAL
Intervention: Progressive walking program (continuous for weeks 1-8 and interval for weeks 9-17)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Walking and stair-climbing group (includes stair climbing)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Progressive walking program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Walking and stair-climbing group
Number of subjects: 15
Study: 28681535

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMBs) present in 30% of patients
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: CMBs
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Treatment assignments (aspirin/clopidogrel vs aspirin/placebo)
Number of subjects: 1278
Study: 26220871

Group type: EXPERIMENTAL
Intervention: Telephone-based support (weekly for 12 weeks, 15-25 min/week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual community care (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Economic evaluation (cost-effectiveness and cost-utility analysis)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 120
Study: 23958393

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl (60 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study: 21030499

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (≥4 cups/day)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Nondrinkers of caffeinated coffee
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (≥4 cups/day) after adjusting for SHBG
Number of subjects: 359
Study: 18985740

Group type: EXPERIMENTAL
Intervention: Aprepitant triple therapy (125 mg p.o. on day 1, 80 mg on days 2 and 3, and 4 mg dexamethasone and ondansetron as specified)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control regimen (16 mg dexamethasone and ondansetron as specified)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aprepitant triple therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 46
Study: 17097819

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (M=0.114 g% breath alcohol concentration [BrAC])
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 15053888

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Junior Medical Staff (JMS)
Number of subjects: 339
Study: 11589530

Group type: EXPERIMENTAL
Intervention: Sertraline 50 to 200 mg/day
Number of subjects: 132
Study: 9465440

Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Graduated exposure
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Progressive deep muscle relaxation training
Number of subjects: 73
Study: 7695265

Group type: EXPERIMENTAL
Intervention: Doxycycline and rifampin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Doxycycline and streptomycin
Number of subjects: 20
Study: 2907877

Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin orally
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin orally
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin intravenously
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29515226

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral morphine (control)
Number of subjects: 0
Study: 27992017

Group type: EXPERIMENTAL
Intervention: Video resources (bedside orientation with a short video and slide presentation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard orientation (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video resources (surgical room topic)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video resources (postoperative unit topic)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video resources (ventilatory support topic)
Number of subjects: 90
Study: 25336467

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 406
Study: 23822534

Group type: EXPERIMENTAL
Intervention: Reading for understanding
Number of subjects: 183

Group type: COMPARATOR
Intervention: Reading to solve a problem
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Think-aloud methodology
Number of subjects: 183
Study: 20827028

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16
Study: 18157705

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (800 mg once-daily for 8 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal liver function)
Number of subjects: 16
Study: 15705041

Group type: EXPERIMENTAL
Intervention: Self-stretching (n = 5)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Static stretching (n = 5)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF-R) (n = 5)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 19
Study: 11876224

Group type: EXPERIMENTAL
Intervention: High flow, high pressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low flow, low pressure
Number of subjects: 40
Study: 10081544

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both sevoflurane and isoflurane anesthesia
Number of subjects: 60
Study: 7752178

Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Enalapril (20 or 40 mg/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 438
Study: 2261364

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Single course of cytotoxic therapy
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Single course of cytotoxic chemotherapy
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Prolonged adjuvant therapy (6 or 7 courses)
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Prolonged cytotoxic therapy
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Prolonged therapy vs. one single course among node-positive patients
Number of subjects: 1127
Study: 399099

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31338642

Group type: EXPERIMENTAL
Intervention: sHNA (online prostate cancer-specific holistic needs assessment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: sHNA
Number of subjects: 41
Study: 31753895

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum, B. infantis, Lactobacillus acidophilus)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 28838685

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 25 μg BID
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 50 μg BID
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study: 26365448

Group type: EXPERIMENTAL
Intervention: Rhythmical Massage (RM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Aroma Oil (RA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham Massage (SM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Salivary Cortisol
Number of subjects: 118
Study: 23278283

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 809

Group type: COMPARATOR
Intervention: Clinical and demographic variables
Number of subjects: 809
Study: 21282425

Group type: EXPERIMENTAL
Intervention: 600 mg oral dose of efavirenz
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 10
Study: 19034460

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 50
Study: 16459222

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet with 30 g of soy protein and 4 g of phytosterols per day (LGID)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard dietary program (American Heart Association Step 1 diet; AHAD)
Number of subjects: 59
Study: 14972080

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional neuroleptics
Number of subjects: 18
Study: 11731893

Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 31
Study: 10919427

Group type: EXPERIMENTAL
Intervention: High moisture‐conserving performance (Group H)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low moisture‐conserving performance (Group L)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High humidity
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low humidity
Number of subjects: 58
Study: 8995494

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week after ingestion of a standard meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in fasting state
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in two divided doses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chronic oral administration of vinorelbine in two divided doses
Number of subjects: 13
Study: 1431363

Group type: EXPERIMENTAL
Intervention: CFPM 2 g/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CFPM 4 g/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: CAZ 2 g/day
Number of subjects: 72
Study: 4051271

Group type: EXPERIMENTAL
Intervention: 50 mg intratracheal aerosolized etidocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 75 mg intratracheal aerosolized etidocaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intratracheal aerosol (Control)
Number of subjects: 45
Study: 30189822

Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 275

Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 275
Study: 26362539

Group type: EXPERIMENTAL
Intervention: Performance feedback‐based app (Nike + Running)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Game-based app (Zombies Run!)
Number of subjects: 28
Study: 24362359

Group type: EXPERIMENTAL
Intervention: Hassle Free Mealtimes Triple P (HFMTP); 2-hour discussion group on positive parenting strategies
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 86
Study: 21928099

Group type: EXPERIMENTAL
Intervention: GF Strong Water Protocol (GFSWP) - oral water intake, independent or supervised access, safe swallowing strategies
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care (control phase) - no water access
Number of subjects: 15
Study: 20039425

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 mg/kg or 8 mg/kg plus methotrexate (MTX)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus methotrexate (MTX)
Number of subjects: 416
Study: 17667889

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IV thrombolytic therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IA thrombolysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IV and IA thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angioplasty and stenting procedures
Number of subjects: 0
Study: 16257877

Group type: EXPERIMENTAL
Intervention: Minimization method
Number of subjects: 459

Group type: COMPARATOR
Intervention: Non-stratified randomization
Number of subjects: 459

Group type: COMPARATOR
Intervention: Stratified randomization
Number of subjects: 459
Study: 11972576

Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablet 2.5 mg
Number of subjects: 471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study: 10102964

Group type: EXPERIMENTAL
Intervention: FCB group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with tripotassium dicitrato bismuthate 240 mg b.d.)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FCL group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with lansoprazole 30 mg daily)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with furazolidone 100 mg b.d.)
Number of subjects: 140

Group type: COMPARATOR
Intervention: MCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with metronidazole 400 mg b.d.)
Number of subjects: 140

Group type: COMPARATOR
Intervention: MCO group (metronidazole-sensitive isolates)
Number of subjects: 140

Group type: COMPARATOR
Intervention: MCO group (metronidazole-resistant strains)
Number of subjects: 140
Study: 8547961

Group type: EXPERIMENTAL
Intervention: Combination of tumor necrosis factor (TNF) and actinomycin D
Number of subjects: 0
Study: 2180849

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Enalapril and Hydrochlorothiazide combination (32.5 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31126121

Group type: EXPERIMENTAL
Intervention: Low-fat dairy foods (4–5 servings/day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D supplements (1500 mg/day Ca and 600 IU/day vitamin D)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo pills (Control)
Number of subjects: 135
Study: 30209154

Group type: EXPERIMENTAL
Intervention: Pilot handover training curriculum (n=69)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard existing curriculum (n=78)
Number of subjects: 147
Study: 26694929

Group type: EXPERIMENTAL
Intervention: Paravertebral-bupivacaine-dexmedetomidine (PBD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Paravertebral-bupivacaine (PB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (C) - sham block with 2 ml normal saline
Number of subjects: 45
Study: 24666144

Group type: EXPERIMENTAL
Intervention: Functional therapy (focused on sleep and daily lifestyle regularity)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control therapy (focused on emotional issues, avoiding sleep and lifestyle regularity)
Number of subjects: 38
Study: 23031406

Group type: EXPERIMENTAL
Intervention: Housing First Ethno‐Racial Intensive Case Management (HF ER‐ICM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group members
Number of subjects: 100
Study: 20459717

Group type: EXPERIMENTAL
Intervention: Implementation strategy for external cephalic version (ECV)
Number of subjects: 100
Study: 17889491

Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide
Number of subjects: 0
Study: 15953714

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 10000 IU thrice weekly subcutaneously (n = 211)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Best supportive care (BSC) (n = 105)
Number of subjects: 316
Study: 12756510

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10368229

Group type: COMPARATOR
Intervention: Fraction II from control samples
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fraction II from hyperoxaluric urine (stone formers)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fraction I from both groups (stone formers and controls)
Number of subjects: 40
Study: 8697548

Group type: EXPERIMENTAL
Intervention: 0.5 L Ringer's lactate (Group 1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 1.0 L Ringer's lactate (Group 2)
Number of subjects: 92
Study: 2003796

Group type: EXPERIMENTAL
Intervention: Scatter photocoagulation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 116
Study: 6609700

Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ibuprofen 400mg three times a day
Number of subjects: 31
Study: 30732654

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Overall discomfort score of the 18-item version of IPREA
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 994
Study: 29555497

Group type: EXPERIMENTAL
Intervention: Outpatient physical therapy (PT) for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unsupervised home exercise program for 6 weeks
Number of subjects: 52
Study: 28011813

Group type: EXPERIMENTAL
Intervention: 2-dose MV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-dose MV with OPV0 in the first week of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-dose MV with OPV0 after the first month of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-dose MV without campaign-OPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-dose MV with campaign-OPV before enrolment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-dose MV with campaign-OPV before enrolment
Number of subjects: 0
Study: 24803100

Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin day(-1) with 75 mg clopidogrel day(-1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 80 mg fluvastatin day(-1) with 75 mg clopidogrel day(-1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 75 mg clopidogrel day(-1) alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel day(-1) with simvastatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel day(-1) with fluvastatin
Number of subjects: 13
Study: 21914768

Group type: EXPERIMENTAL
Intervention: TC + TSE information group
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: TC information group
Number of subjects: 443

Group type: COMPARATOR
Intervention: No information control group
Number of subjects: 443
Study: 19276396

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks (arm A)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B)
Number of subjects: 390
Study: 17178252

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etafilcon A
Number of subjects: 20
Study: 15219332

Group type: EXPERIMENTAL
Intervention: Tobacco deprivation for 5 hours
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (not deprived of tobacco)
Number of subjects: 78
Study: 12150702

Group type: EXPERIMENTAL
Intervention: Cytokine modulation strategies (blocking or attenuating TNF-alpha and IL-1beta activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental therapies involving IL-10, transforming growth factor-beta, granulocyte colony-stimulating factor, and IFN-phi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less known cytokines such as macrophage migration inhibitory factor and high mobility group 1 protein
Number of subjects: 0
Study: 9638985

Group type: EXPERIMENTAL
Intervention: Combination of behenoyl‐cytosine‐arabinoside (BHAC), daunorubicin (DNR), 6‐mercaptopurine (6‐MP) and prednisolone (PSL)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Residual leukemic cell counts of less than 300 cells/microl in the bone marrow at the end point of induction therapy
Number of subjects: 59
Study: 8074068

Group type: EXPERIMENTAL
Intervention: 42 g fat
Number of subjects: 8

Group type: COMPARATOR
Intervention: 31 g fat
Number of subjects: 8
Study: 2698940

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 16
Study: 29980128

Group type: EXPERIMENTAL
Intervention: Inpatient and day hospital treatment
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Nonresponse at the end of treatment
Number of subjects: 518
Study: 28489240

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the tonsillar capsule during electrical tonsillectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline injection during electrical tonsillectomy
Number of subjects: 0
Study: 25589220

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose with ketoconazole 400 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole 400 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib in the presence of ketoconazole
Number of subjects: 0
Study: 24267874

Group type: EXPERIMENTAL
Intervention: Improved hand and respiratory hygiene measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control households (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Households with confirmed influenza A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Households with confirmed influenza B
Number of subjects: 0
Study: 21385289

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 7
Study: 18460478

Group type: EXPERIMENTAL
Intervention: Chitosan 4.5 g per day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Chitosan 6.75 g per day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Glucomannan 6.75 g per day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (0 g chitosan)
Number of subjects: 65
Study: 16164527

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study: 11818160

Group type: EXPERIMENTAL
Intervention: Two doses of AVA 4 weeks apart IM
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: IM administration of AVA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: SQ administration of AVA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Longer dose interval between first two doses
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (licensed schedule and route)
Number of subjects: 173